EWTX - Edgewise Therapeutics, Inc.
IEX Last Trade
29.71
0.110 0.370%
Share volume: 14,103
Last Updated: Thu 26 Dec 2024 08:30:02 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$29.60
0.11
0.37%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-1.20%
1 Month
-7.67%
3 Months
13.97%
6 Months
69.45%
1 Year
211.13%
2 Year
247.25%
Key data
Stock price
$29.71
DAY RANGE
$28.90 - $29.87
52 WEEK RANGE
$10.10 - $38.12
52 WEEK CHANGE
$157.57
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Kevin Koch
Region: US
Website: edgewisetx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: edgewisetx.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.
Recent news